Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

16.60 -0.20 (-1.19%)
Streaming Delayed Price Updated: 11:58 AM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
35 36 Next >
News headline image
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud
News headline image
SRPT Investigation Reminder: Kessler Topaz Meltzer &amp; Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
News headline image
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law
From Bleichmar Fonti & Auld LLP
Via Business Wire
News headline image
Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (28 Ratings) ↗
 
Via Benzinga
News headline image
US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '...Avoid Getting Whipsawed By Noise,' Says Expert ↗
U.S. stock futures were trading lower on Tuesday following Monday's advanced. Futures of major benchmark indices were lower in premarket. 
Via Benzinga
Topics Government
News headline image
Market Monitor News June 17 (ROKU, Advanced Micro Devices UP - Sarepta Therapeutics DOWN) ↗
Markets rebound on hopes of Iran de-escalation; oil drops, Roku surges on Amazon deal, Fed decision looms. 
Via Chartmill
Topics Economy
News headline image
Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone ↗
 
Via Benzinga
Topics Stocks
News headline image
1 Oversold Stock Primed to Rebound and 2 to Steer Clear Of
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling... 
Via StockStory
News headline image
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud
News headline image
SRPT Investigation Reminder: Kessler Topaz Meltzer &amp; Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
News headline image
Monday's session: top gainers and losers ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
What the Options Market Tells Us About Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
Why Sarepta Therapeutics (SRPT) Stock Is Down Today
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a second death linked to its Duchenne muscular dystrophy gene therapy,.... 
Via StockStory
News headline image
Top movers in Monday's session ↗
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Sarepta Therapeutics Stock Alert: Investors of Sarepta May Have Legal Claims and Are Encouraged to Contact Kehoe Law Firm, P.C. - SRPT
Via ACCESS Newswire
News headline image
These stocks are gapping in today's session ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
US Stocks Higher; Dow Jumps Over 400 Points ↗
 
Via Benzinga
Topics Stocks
News headline image
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Stock Plunges On Multiple Downgrades Following Patient Death: Retail Questions ‘Crazy’ Price Targets ↗
Piper Sandler cut its Elevidys peak sales estimate to $1.7 billion from $2.4 billion. 
Via Stocktwits
Topics Death
News headline image
Sarepta Therapeutics Plummets 43% After A Second Gene Therapy Recipient Dies ↗
The company is working with an independent group to determine if there's a better immunosuppressive regimen. 
Via Investor's Business Daily
Topics Death Government
News headline image
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Monday's pre-market session: top gainers and losers ↗
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Dow Futures Edge Up As Israel-Iran Conflict Spares Oil Capacity: US Steel, Tesla, Victoria’s Secret, Sarepta Among Stocks To Watch ↗
While Dow Jones futures gained 0.41% at the time of writing, the S&P 500 futures rose 0.48%. 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy ↗
Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause. 
Via Benzinga
Topics Death
News headline image
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Sarepta Pauses DMD Gene Therapy Trial After Second Death; Retail Traders Brush Off Risk ↗
BMO Capital downgraded the stock, warning of rising regulatory uncertainty and potential revenue impact. 
Via Stocktwits
News headline image
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
From Sarepta Therapeutics, Inc.
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.